Business and strategy: acquisition: Bayer/OSI

Article Abstract:

Leverkusen, Germany-based Bayer Corp. has acquired the assets of Uniondale, NY-based OSI Pharmaceuticals diagnostics business, which includes the assets of OSI's wholly owned diagnostics subsidiary Oncogene Science Diagnostics (OSDI), based in Cambridge, MA.

Bayer Corp., OSI Pharmaceuticals Inc., OSIP

---

The Latest Drug Merger. Will Two Second-Tier Firms Make One Strong Company?

Article Abstract:

The merger of American Home Products and Monsanto will create a company worth $96 billion. Also mentioned is Wyeth-Lederle Vaccines' acquisition of Apollon Inc.

Drugs & Pharmaceuticals, Pharmaceutical and Medicine Manufacturing, Vaccines & Antigens for Human Use, Biological Product (except Diagnostic) Manufacturing, Drugs, Biological products exc. diagnostic, Abstract, Biological products, Monsanto Co., MTC, AHP, Wyeth, Wyeth-Lederle Vaccines, Apollon Inc.

---

Perkin-Elmer: drug screening agreement provides HTS for combinatorial libraries

Article Abstract:

Ontogeny Inc. and PE Biosystems Div. have formed a drug screening partnership along with Tropix to extend Ontogeny's ability to identify the pathways critical to a number of significant diseases, including cancer, diabetes and osteoarthritis.

Product development, Biochemistry, Research and Development in the Physical, Engineering, and Life Sciences, Anticancer Drugs, Antidiabetic Preparations, Antiarthritic Analgesic Preps, Brief Article, Hypoglycemic agents, Antineoplastic agents, Ontogeny Inc., Antiarthritic agents, PE Biosystems Group, Tropix Inc.

Similar abstracts:

• Abstracts: Pharmanetics/Aventis: agreement to develop theranostic test for enoxaparin
• Abstracts: Genotypic/Phenotypic resistance testing: HIV drug resistance testing tjo be introduced in the U.S. Homocysteine: first automated homocysteine cleared by FDA
• Abstracts: Drug discovery: Affymetrix: Affymetrix to provide arrays to Rhone-Poulenc. Infectious disease: Antex
• Abstracts: The latest diagnostic trend: linking the point of care to the lab. Business and strategy: global standards
• Abstracts: Award: XTRANA/ Department of Defense: contract to delelop nucleic acid-based test for coliform contamination

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.